Хлебные крошки
- Главная
-
Аналитика
-
Акции
Акции внутренные
Ionis Pharmaceuticals, Inc. IONS
$35.53
-$0.06 (-0.17%)
На 18:00, 12 мая 2023
+31.13%
Потенциал через год
Ранг: 2
Ключевые показатели
-
Marketcap
5094075200.00000000
-
week52high
48.82
-
week52low
32.62
-
Revenue
587000000
-
P/E TTM
-47
-
Beta
0.53529400
-
EPS
-1.85000000
-
Last Dividend
0.00000000
-
Next Earnings Date
03 мая 2023 г. в 15:30
Описание компании
Ionis Pharmaceuticals, Inc. discovers and develops RNA-targeted therapeutics in the United States. The company offers SPINRAZA for spinal muscular atrophy (SMA) in pediatric and adult patients; TEGSEDI, an injection for the treatment of polyneuropathy of hereditary transthyretin-mediated amyloidosis in adults; and WAYLIVRA, a treatment for familial chylomicronemia syndrome and familial partial lipodystrophy. It also develops medicines for various indications that are in phase 3 study, including Eplontersen as a monthly self-administered subcutaneous injection to treat all types of TTR amyloidosis; Olezarsen for patients with severe hypertriglyceridemia (SHTG); Donidalorsen for patients with hereditary angioedema; ION363 for patients with amyotrophic lateral sclerosis; Pelacarsen for patients with established cardiovascular disease and elevated lipoprotein(a); and Tofersen to inhibit the production of superoxide dismutase 1. In addition, the company develops medicines for metabolic diseases, infectious diseases, renal diseases, ophthalmic diseases, and cancer. It has a strategic collaboration with Biogen Inc.; and collaboration and license agreement with AstraZeneca, Bayer AG, GlaxoSmithKline plc, Novartis AG, Roche, Janssen Biotech, Inc., and Flamingo Therapeutics, Inc. Ionis Pharmaceuticals, Inc. was founded in 1989 and is based in Carlsbad, California.
Рекомендации
аналитиков
Рекомендации аналитиков
| Grading company | New grade | Previous grade | Recommendation date |
|---|---|---|---|
| RBC Capital | Outperform | Outperform | 10 авг 2022 г. |
| Citigroup | Sell | Sell | 10 авг 2022 г. |
| Piper Sandler | Overweight | Overweight | 26 июл 2022 г. |
| SVB Leerink | Market Perform | Market Perform | 21 июн 2022 г. |
| Morgan Stanley | Underweight | Underweight | 09 мая 2022 г. |
| Morgan Stanley | Overweight | Underweight | 09 сент 2022 г. |
| SVB Leerink | Market Perform | Market Perform | 10 ноя 2022 г. |
| Morgan Stanley | Overweight | Overweight | 10 ноя 2022 г. |
| Citigroup | Sell | Sell | 10 ноя 2022 г. |
| Morgan Stanley | Equal-Weight | Overweight | 21 дек 2022 г. |
| Piper Sandler | Overweight | Overweight | 19 янв 2023 г. |
| SVB Leerink | Market Perform | Market Perform | 23 янв 2023 г. |
Свежие комментарии
Свежие комментарии
Оставьте свой голос
Оставьте свой голос
Анонимное голосование
Будет ли рост российского рынка к концу года?
-
Да
87% -
Нет
12%
Проголосовал 8 человек
Покожие компании
Новостная лента
компании
Insider Summary
Insider Summary
| Reporting Name | Acquistion/Disposition | Owned | Transacted | Transaction Date |
|---|---|---|---|---|
| O'NEIL PATRICK R. | D | 39679 | 4500 | 31 янв 2023 г. |
| O'NEIL PATRICK R. | D | 44179 | 4500 | 30 янв 2023 г. |
| Monia Brett P | D | 120863 | 25066 | 18 янв 2023 г. |
| O'NEIL PATRICK R. | D | 48679 | 7836 | 18 янв 2023 г. |
| Schneider Eugene | D | 22326 | 4752 | 18 янв 2023 г. |
| Swayze Eric | D | 30041 | 5631 | 18 янв 2023 г. |
| Baroldi Joseph | D | 851 | 375 | 18 янв 2023 г. |
| BENNETT C FRANK | D | 67855 | 6978 | 18 янв 2023 г. |
| Cadoret-Manier Onaiza | D | 18538 | 3748 | 18 янв 2023 г. |
| Geary Richard S | D | 70483 | 7873 | 18 янв 2023 г. |
Новостная лента
Ionis to present at upcoming investor conferences
PRNewsWire
09 мая 2023 г. в 07:05
CARLSBAD, Calif. , May 9, 2023 /PRNewswire/ -- Ionis Pharmaceuticals, Inc. (Nasdaq: IONS) today announced that management will participate in fireside chats at the following investor conferences: RBC Capital Markets Global Healthcare Conference on Tuesday, May 16, 2023 Goldman Sachs 44th Annual Global Healthcare Conference on Monday, June 12, 2023 A live webcast of the presentations can be accessed on the Investors & Media section of the Ionis website at www.ionispharma.com.
Ionis (IONS) Q1 Earnings Surpass Estimates, Sales Match
Zacks Investment Research
04 мая 2023 г. в 10:41
Ionis (IONS) reports a narrower-than-expected Q1 loss. Sales come in line with estimates.
Ionis Pharmaceuticals (IONS) Reports Q1 Loss, Tops Revenue Estimates
Zacks Investment Research
03 мая 2023 г. в 09:55
Ionis Pharmaceuticals (IONS) came out with a quarterly loss of $0.87 per share versus the Zacks Consensus Estimate of a loss of $1. This compares to loss of $0.46 per share a year ago.
Biotech/Drug Stocks' Q1 Earnings Due May 3: UTHR, PCRX & More
Zacks Investment Research
02 мая 2023 г. в 14:32
Let us take a look at what's in store for biotech/drug stocks UTHR, PCRX, CORT, AMRN and IONS, which are scheduled to report on May 3.
3 Biotech Stocks to Sell Before They're 6 Feet Under
InvestorPlace
24 апр 2023 г. в 14:37
In a high-interest-rate environment, cash is king. All biotech companies will need to continue spending to finance their R&D.